

PRESS CLIPPING SHEET

PUBLICATION:	Daily News
DATE:	16-Oct-2017
COUNTRY:	Egypt
CIRCULATION:	80,000
TITLE :	First approved therapy in Egypt indicated for second-line stomach cancer launched
PAGE:	06
ARTICLE TYPE:	Agency-Generated News
REPORTER:	Staff Report
AVE:	9,300

First approved therapy in Egypt indicated for second-line stomach cancer launched

Elly Lilly held a press conference in collaboration with the International Gastro Intestinal Liver and Uro-Oncology conference, one of the activities organised by the BGICS. The press conference celebrated the launch of ramucirumab, the first second-line treatment for stomach cancer to receive international pharmaceutical organization authorization in Egypt.

"Gastric cancer remains the fifth most common form of cancer in the world," said Dr. Yasser Abdel Kader, professor of oncology and director of the research unit at the oncology department at Cairo University's faculty of medicine. "Despite a drop in overall mortality because

of incidence decrease, gastric cancer remains the fifth most commonly diagnosed type of cancer and the third most common cause of premature death from cancer globally," he said.

"Gastric cancer is an extremely serious disease, with very poor prognosis," said Dr. Fouad Abu-Taleb, professor and head of the medical oncology department at Zagazig University's faculty of medicine. "In Egypt, by applying age-specific incidence rates for 2013 to successive populations, it would lead to a progressive increase in the number of gastric cancer cases, to rise from 1.7% of all new cancer cases in 2013 to reach 2.6% in 2025 (1.5-fold increase) and 5.1% in 2050 (almost 3-fold increase)," he added.